Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Role of Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma
Bin‐Yan Zhong, Zhi‐Cheng Jin, Jian-Jia Chen, et al.
Journal of Clinical and Translational Hepatology (2022) Vol. 000, Iss. 000, pp. 000-000
Open Access | Times Cited: 53

Showing 1-25 of 53 citing articles:

Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study
Bruno Sangro, Masatoshi Kudo, Joseph P. Erinjeri, et al.
The Lancet (2025) Vol. 405, Iss. 10474, pp. 216-232
Closed Access | Times Cited: 15
Sustained release hypoxia-activated prodrug-loaded BSA nanoparticles enhance transarterial chemoembolization against hepatocellular carcinoma
Ying-Hong Hao, Wenzhi Zhu, Jie Li, et al.
Journal of Controlled Release (2024) Vol. 372, pp. 155-167
Closed Access | Times Cited: 9
Targeting ferroptosis: the role of non-coding RNAs in hepatocellular carcinoma progression and therapy
Weijia Wang, Behishta Hashimi, Ping Wang
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Closed Access | Times Cited: 1
Effect of external beam radiation therapy versus transcatheter arterial chemoembolization for non-diffuse hepatocellular carcinoma (≥ 5 cm): a multicenter experience over a ten-year period
Ke Su, Fei Wang, Xueting Li, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 20
Locoregional therapies for hepatocellular carcinoma: The current status and future perspectives
Jian‐Jian Chen, Zhi‐Cheng Jin, Bin‐Yan Zhong, et al.
United European Gastroenterology Journal (2024) Vol. 12, Iss. 2, pp. 226-239
Open Access | Times Cited: 6
Efficacy and safety of hepatic artery infusion chemotherapy combined with tyrosine kinase inhibitors plus programmed death-1 inhibitors for hepatocellular carcinoma refractory to transarterial chemoembolization
Long-Wang Lin, Kun Ke, Leye Yan, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 11
Prognostic Performance of the China Liver Cancer Staging System in Hepatocellular Carcinoma Following Transarterial Chemoembolization
Bin‐Yan Zhong, Jian-Qiang Jiang, Jun‐Hui Sun, et al.
Journal of Clinical and Translational Hepatology (2023) Vol. 000, Iss. 000, pp. 000-000
Open Access | Times Cited: 11
Sultan’s Score: A Novel Predictive Score to Predict Complete Response Following Drug-Eluting Bead Chemoembolization
Sultan Alharbi
Cureus (2025)
Open Access
Dual Inhibition of Gpx4 and Lcn2 Via Mir-214-Loaded Iron Oxide Nanoparticles for Enhancing Ferroptosis in Liver Cancer
Junling An, Hao Li, Wenjing Wen, et al.
(2025)
Closed Access
Immunotherapy and Radiation Therapy Combinatorial Approaches in Hepatocellular Carcinoma
Alireza Tojjari, James Yu, Anwaar Saeed
Cancers (2024) Vol. 16, Iss. 5, pp. 1058-1058
Open Access | Times Cited: 3
A refined prediction model for survival in hepatocellular carcinoma patients treated with transarterial chemoembolization
Hae Lim Lee, Seok‐Hwan Kim, Hee Yeon Kim, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 3
TACE combined Lenvatinib plus Camrelizumab versus TACE alone in efficacy and safety for unresectable hepatocellular carcinoma: a propensity score-matching study
Zhihong Tang, Tao Bai, Tao Wei, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 3
Survival of patients with non-viral hepatocellular carcinoma treated with trans-arterial chemoembolization: A multicenter cohort study
Hend Ibrahim Shousha, Eman Barakat, Eman Rewisha, et al.
Arab Journal of Gastroenterology (2025)
Closed Access
Drug-eluting beads transarterial chemoembolization vs conventional transarterial chemoembolization in the treatment of hepatocellular carcinoma in adult patients: a systematic review and update meta-analysis of observational studies
T. S. Chernyshenko, Roman A. Polkin, Е. Р. Двойникова, et al.
Frontiers in Oncology (2025) Vol. 14
Open Access
Prediction Model of Survival in Unresectable HCC with Central Bile Duct Invasion Receiving TACE After Biliary Drainage: TEMP Score
Wenzhe Fan, Xinlin Zheng, Weihong Zhang, et al.
Journal of Hepatocellular Carcinoma (2025) Vol. Volume 12, pp. 615-628
Open Access
Development of a Nomogram for Prognostic Prediction of Large Hepatocellular Carcinoma With HBV After TACE Combined Conversion Therapy
Wei Xu, Xia Ding, Yan Xu, et al.
Hepatic Medicine Evidence and Research (2025) Vol. Volume 17, pp. 1-12
Open Access
Autophagy plays a pro-apoptotic role in arsenic trioxide-induced cell death of liver cancer
Zhengting Deng, Shufang Liang, Guo-kai Huang, et al.
Journal of Integrative Medicine (2024) Vol. 22, Iss. 3, pp. 295-302
Closed Access | Times Cited: 3
Which is the best TACE agent for patients with different NLR hepatocellular carcinomas? A systematic review and network meta-analysis
Shuai Wang, Hefeng Geng, Yizhen Li, et al.
Heliyon (2024) Vol. 10, Iss. 9, pp. e30759-e30759
Open Access | Times Cited: 3
Development and validation of a predictive scoring system for post-transarterial chemoembolization pain management in liver cancer patients
Ke You, Jia‐Guo Wang, Jie Xu, et al.
Journal of Gastrointestinal Oncology (2024) Vol. 15, Iss. 1, pp. 425-434
Open Access | Times Cited: 2
Efficacy and safety of transarterial chemoembolization combined with targeted therapy and immunotherapy versus with targeted monotherapy in unresectable hepatocellular carcinoma: A systematic review and meta-analysis
Jingwen Feng, Yi Zhao, Lin Zhai, et al.
Medicine (2024) Vol. 103, Iss. 18, pp. e38037-e38037
Open Access | Times Cited: 2
TACE plus lenvatinib and tislelizumab for intermediate-stage hepatocellular carcinoma beyond up-to-11 criteria: a multicenter cohort study
Song Chen, Shuang‐Yan Tang, Feng Shi, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
Immune-targeted therapy with transarterial chemo(embolization) for unresectable HCC: a systematic review and meta-analysis
Huipeng Fang, Qiao Ke, Shiji Wu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
Transarterial chemoembolization refractoriness in hepatocellular carcinoma: Chinese College of Interventionalists definition and consensus statement
Bin‐Yan Zhong, Shen Zhang, Haidong Zhu, et al.
Chinese Medical Journal (2024) Vol. 137, Iss. 17, pp. 2040-2042
Open Access | Times Cited: 2
Camrelizumab combined with transcatheter arterial chemoembolization and sorafenib or lenvatinib for unresectable hepatocellular carcinoma: A multicenter, retrospective study
Xiumei Jiang, Pan Wang, Ke Su, et al.
Annals of Hepatology (2024), pp. 101578-101578
Open Access | Times Cited: 2
Synergistic Nanomedicine: Photodynamic, Photothermal and Photoimmune Therapy in Hepatocellular Carcinoma: Fulfilling the Myth of Prometheus?
Laura Marinela Ailioaie, Constantin Ailioaie, Gerhard Litscher
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 9, pp. 8308-8308
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top